MOTS-c

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Mostly laboratory or animal evidence. The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Cell and animal studies report effects on metabolic signaling, stress responses, and exercise-related physiology. These findings do not establish benefit, safety, or an anti-aging effect in humans.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Research only

  MOTS-c is not an FDA-approved drug. FDA has identified it among bulk substances for which compounded use may present significant safety risks.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• Elamipretide / SS-31Both are discussed in mitochondrial research; only elamipretide has a narrow FDA-approved product.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   Review of MOTS-c therapeutic research

   MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. 2023.

   PubMed-indexed review · Published Jan 1, 2023 · Accessed Jul 22, 2026 · Systematic review

   Open source
2. 2

   FDA: Certain bulk drug substances may present significant safety risks

   U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.

   U.S. Food and Drug Administration · Published Jul 22, 2026 · Accessed Jul 22, 2026 · Regulatory source

   Open source